Smith & Nephew Share Discussion Threads

[foreverbull] 27/7/2024 07:29

Hopefully some of this optimism will be reflected in SN's upcoming results... let's seeHttps://www.pharmiweb.com/press-release/2024-07-26/joint-replacement-market-to-reach-usd-27-billion-by-2032-at-a-43-of-cagrJoint Replacement Market to Reach USD 27 Billion by 2032 at a 4.3% of CAGRMARKITWIREDThe global joint replacement market is on a strong growth trajectory, with a recent analysis by Future Market Insights revealing that the market held a valuation of USD 17.1 billion in 2021. The market is projected to expand at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2032, reaching an estimated USD 27 billion by the end of the forecast period.According to the report, knee replacement procedures are anticipated to be the leading revenue-generating segment within the joint replacement market. This segment is expected to grow at a CAGR of over 4.1% from 2022 to 2032, driven by increasing prevalence of knee-related disorders and advancements in surgical technologies.The global joint replacement market is expected to develop significantly as the population ages and joint-related disorders become more common. The market is growing as a result of advancements in surgical methods and medical technology that give patients better results and faster recovery times.Get your PDF – Sample ReportWith the goal of restoring mobility, reducing pain, and improving overall quality of life, joint replacement procedures are becoming more and more popular as a therapeutic option for those with debilitating joint disorders. This is reflected in the market's predicted rise.It is anticipated that major industry participants will take advantage of these expansion prospects by emphasizing innovation, product development, and tactical partnerships in order to meet changing patient demands and preferences. Additionally, investments in research and development projects focused at boosting surgical results and implant longevity are predicted to further push market expansion in the coming years.Key Takeaways:The global joint replacement market reached a valuation of US$17.1 billion in 2021, according to a newly released analysis report by Future Market Insights.With a projected CAGR of 4.3% from 2022 to 2032, the market is expected to reach a staggering US$27 billion by 2032.Knee replacements are anticipated to be the highest revenue-generating segment, growing at a CAGR exceeding 4.1% from 2022 to 2032.Competitive Analysis:The joint replacement market is fragmented, with many large and small companies competing. Smith+Nephew, DJO, LLC, Johnson & Johnson Services Inc., Stryker, Zimmer Biomet, Arthrex Inc., Exactech Inc., Conformis, MicroPort Orthopedics, and Corin Group are some of the major players in the market.Some of the recent developments of Joint Replacement Market key providers are as follows:In January 2022, Engage Surgical, the owner of the only cement-less unicompartmental knee system commercially accessible in the United States, was acquired by Smith+Nephew, a multinational medical technology business.In February 2021, MicroPort Orthopedics added hyaluronic acid-coated collared hip stems and affixed collared hip stems to their hip stems lineup.In January 2021, Stryker purchased OrthoSensor, Inc., a forerunner in the digital evolution of full joint replacement.In July 2018, Corin announced that it will offer the Trinity Dual Mobility System for Hip Replacement.

[foreverbull] 27/7/2024 01:41

Https://finance.yahoo.com/news/value-investors-buy-smith-nephew-134014418.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvLnVrLw&guce_referrer_sig=AQAAAHiUvNvWkGtESbuNH-DCZFGA2buU3TGd8l60rVhiPEMunvMoRFpdk5UiN6L5op2aAq1Jb167O-0axJdgGmghMm2vL94_Z8PDWGRC9qbBtFt2TSRLl-LEa68_qztKsp62sW-D4V15uJxg7KfAPHJvjYtIdJJABgcsN8g3LYcm1o2wShould Value Investors Buy Smith & Nephew SNATS (SNN) Stock?Zacks Equity ResearchWed, Jul 24, 2024 at 2:40 PM GMT+12 min readOne company to watch right now is Smith & Nephew SNATS (SNN). SNN is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 14.87. This compares to its industry's average Forward P/E of 20.26. Over the past year, SNN's Forward P/E has been as high as 17.45 and as low as 11.69, with a median of 13.91.SNN is also sporting a PEG ratio of 1.13. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. SNN's PEG compares to its industry's average PEG of 2.07. SNN's PEG has been as high as 1.60 and as low as 0.98, with a median of 1.27, all within the past year.Another valuation metric that we should highlight is SNN's P/B ratio of 2.38. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 6.95. Over the past 12 months, SNN's P/B has been as high as 2.61 and as low as 1.80, with a median of 2.19.These are only a few of the key metrics included in Smith & Nephew SNATS's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, SNN looks like an impressive value stock at the moment.

[keyno] 26/7/2024 16:10

ForeverBull: I know no more than what I've written above, which appeared in an email from II sent out on Wednesday.

[foreverbull] 24/7/2024 11:10

Do you've the link please?

[keyno] 24/7/2024 10:15

Deutsche Bank starts Smith & Nephew with 'buy' - price target 1,350 pence

[foreverbull] 18/7/2024 15:26

Are you meaning to say he could have bought SN shares which would have helped him make (or loose) more money?

[csalvage] 18/7/2024 15:00

Citadel's Ken Griffin buys a stegosaurus for $45 million in a record auction salehttps://www.cnbc.com/2024/07/18/citadels-ken-griffin-buys-a-stegosaurus-for-45-million-in-a-record-auction-sale.html?__source=androidappshare

[justiceforthemany] 16/7/2024 14:20

What rise?
Cevian need to accumulate more stock.

[foreverbull] 11/7/2024 15:35

Nice rise ...

[justiceforthemany] 04/7/2024 18:39

Citadel increased their short yesterday, just before the 7% rally!

[edwardt] 04/7/2024 10:09

time for a spin off of the wound care division...

[foreverbull] 04/7/2024 09:17

Shares in Smith & Nephew PLC (LSE:SN) jumped after it was revealed that activist investor Cevian Capital has built a stake in the replacement hip and knee maker. The Swedish hedge fund, which has previously taken positions in Aviva, Vodafone, Pearson and RSA Insurance, declared a stake of 5.02%.S&N shares, which hit almost a decade low last year and have fallen around 19% over the past 12 months, jumped 6.5% to 1,050.5p in early trades on Thursday. Cevian's strategy is to acquire significant minority ownership positions in European public companies and "work as an owner" to improve value.According to its website, the fund typically acquires stakes in companies that it believes have leading market positions, produce strong cashflows, benefit from robust long-term demand dynamics and "are overlooked, misunderstood or out-of-favor with investors".

[foreverbull] 04/7/2024 08:49

Hopefully Norges Bank is taking a lead in the steps to ousting the CEO ?

[foreverbull] 04/7/2024 08:46

Smith & Nephew Snats (SN) has released an update.Smith & Nephew PLC has notified a change in major holdings, with Norges Bank crossing the threshold on June 28, 2024, now holding a total of 3.054% voting rights. This significant financial activity, reported on July 3, 2024, reflects a combination of voting rights attached to shares and financial instruments, amounting to over 26 million voting rights within the medical equipment manufacturer.

[bomber13] 04/7/2024 07:47

An activist investor with 5% of S&N may be just what is needed to shake things up a bit ?

[foreverbull] 02/7/2024 08:57

And continues ....

[justiceforthemany] 26/6/2024 23:23

Investors need to be contacting Investor Relations and ask for the CEO Deepak Nath to go. Buck stops at the top.
Abysmal.

[socionomics] 07/6/2024 07:54

The good news for SN investors is that we're heading into Wave 5, so we should break the £20 high in due course. The bad news is that's a 5-6 year move. Might be a little too boring for many, but for me it's an easy SIPP play.

DYOR as always.

[hem007] 05/6/2024 13:55

It's not even at 1090 let alone on it's way to 12

[keyno] 05/6/2024 12:38

I wish.........

[suetballs] 05/6/2024 10:25

ubs buy note - raises tp to £12 from £10.90.
Suet

[value viper] 05/6/2024 10:24

Interesting spike

[suetballs] 05/6/2024 10:19

A bit of blue today - makes a change.
Suet

[justiceforthemany] 23/5/2024 21:55

The share price action here is woeful.Do people no longer need hips and knees? Of course they do. Blatant manipulation.